Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zhangzhou Pientzehuang Pharmaceutical Co EBITDA Margin % Related Terms
Zhangzhou Pientzehuang Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co EBITDA Margin % Chart
Zhangzhou Pientzehuang Pharmaceutical Co Annual Data
SHSE:600436 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Zhangzhou Pientzehuang Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhangzhou Pientzehuang Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) has a EBITDA Margin % of 32.20% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. This is near median its historical median of 31.23. Over the past decade, Zhangzhou Pientzehuang Pharmaceutical Co's EBITDA Margin % has ranged from 26.30 to 37.84. According to the industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #192 out of 960 companies in the Drug Manufacturers industry, placing it in the top 20%.
Is Zhangzhou Pientzehuang Pharmaceutical Co's EBITDA Margin % too high?
Zhangzhou Pientzehuang Pharmaceutical Co's current EBITDA Margin % of 32.20% is near median its 10-year median of 31.23. Over the past 10 years, this metric has ranged from a low of 26.30 to a high of 37.84. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Zhangzhou Pientzehuang Pharmaceutical Co's value of 32.20% is 157.3% above this industry median. Based on the distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #192 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhangzhou Pientzehuang Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhangzhou Pientzehuang Pharmaceutical Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #192 out of 960 companies for EBITDA Margin %. This places Zhangzhou Pientzehuang Pharmaceutical Co in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Zhangzhou Pientzehuang Pharmaceutical Co's value of 32.20% is 157.3% above this benchmark. Historically, Zhangzhou Pientzehuang Pharmaceutical Co's own EBITDA Margin % has ranged from 26.30 to 37.84 over the past decade. While the company's 10-year median is 31.23 vs. the industry median of 12.52, Zhangzhou Pientzehuang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhangzhou Pientzehuang Pharmaceutical Co's current EBITDA Margin % of 32.20% is 157.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhangzhou Pientzehuang Pharmaceutical Co's current EBITDA Margin % is 32.20%, which is near median its own 10-year median of 31.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhangzhou Pientzehuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥172.67, compared to a current price of ¥146.63 — trading 15.1% below its estimated fair value. The current EBITDA Margin % is 32.20%, which is near median its 10-year median of 31.23 and 157.3% above the Drug Manufacturers industry median of 12.52. Zhangzhou Pientzehuang Pharmaceutical Co's overall GF Score™ is 86/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436), the current EBITDA Margin % is 32.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) Overvalued in 2026?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥146.63 is trading 15.1% below its estimated GF Value™ of ¥172.67.
GuruFocus considers Zhangzhou Pientzehuang Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600436:
EBITDA Margin %: 32.20% (near median its 10-year median of 31.23)
GF Value™: ¥172.67 vs. price of ¥146.63 (15.1% below fair value)
Industry Position: 157.3% above the Drug Manufacturers median (#192 of 960)
No single metric tells the full story. See the SHSE:600436 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhangzhou Pientzehuang Pharmaceutical Co Business Description
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
86GF Score
Get the complete analysis for SHSE:600436
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600436 has been successfully added to your 
